Basilea, Stiefel complete dermatology drug transaction
As part of the agreement, Stiefel will acquire global rights to Toctino and Basilea’s existing distribution agreements for the drug. Basilea, which will receive an upfront payment of
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The research and development project will leverage Pacific Biosciences’ proprietary zero-mode waveguide (ZMW) technology and imec’s knowledge in nanophotonics, CMOS sensors, technology integration and fabrication. Pacific Biosciences president